Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster discussion session - Immunotherapy of cancer 1

4961 - A Phase 2a Trial to Assess the Safety and Efficacy of BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC)


20 Oct 2018


Poster discussion session - Immunotherapy of cancer 1


Clinical Research;  Immunotherapy

Tumour Site

Pancreatic Adenocarcinoma


Manuel Hidalgo


Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288


M. Hidalgo1, R. Epelbaum2, B.M. Wolpin3, S.M. Stemmer4, R. Geva5, T. Golan6, E. Borazanci7, M. Borad8, K.S. Pedersen9, J.O. Park10, R. Ramirez11, A. Peled12, T.M. Lustig13, O. Bohana Kashtan14, O. Rosenfeld13, E. Sorani14, K. Schlienger15, A. Vainstein Haras13, D.D. Von Hoff7

Author affiliations

  • 1 Division Hematology Oncology, Beth Israel Deaconess Med. Center, 2215 - Boston/US
  • 2 Oncology, Rambam Health Care Center, 31096 - Haifa/IL
  • 3 Gastrointestinal Cancer Center, Dana Farber Cancer Institute, Boston/US
  • 4 Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 49100 - Petah Tikva/IL
  • 5 Oncology, Tel Aviv Sourasky Medical Center-(Ichilov), 64239 - Tel Aviv/IL
  • 6 Oncology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
  • 7 Oncology, Honor Health/TGen, Scottsdale/US
  • 8 Oncology, Mayo Clinic Cancer Center, 85259 - Scottsdale/US
  • 9 Oncology, Washington University School of Medicine, St Louis/US
  • 10 Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 11 Oncology, Ochsner Medical Centre, Jefferson/US
  • 12 Goldyne Savad Institute Of Gene Therapy, Hebrew University of Jerusalem, Jerusalem/IL
  • 13 Clinical, BioLineRx Ltd, Modi'in/IL
  • 14 Research And Development, BioLineRx Ltd, Modi'in/IL
  • 15 Early Development Oncology, Merck & Co, 07065 - Rahway/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4961


Current treatment options for PDAC patients are limited by poor survival and toxicity. Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are successful in treating several cancer types; however, PDAC remains refractory. In PDAC mouse models, blockade of the CXCR4/CXCL12 axis promotes tumor infiltration of T cells and synergistic anti-tumor effects when combined with anti-PD-1/anti-PD-L1. We have shown that the high affinity CXCR4 antagonist BL-8040 given as monotherapy promoted infiltration of T cells into metastatic liver lesions in PDAC patients. Here, we report efficacy data from this ongoing Phase 2a clinical trial designed to assess the ability of BL-8040 to enhance responsiveness to the anti-PD-1 ICI Pembrolizumab in patients with metastatic PDAC.


Phase 2a study consisting of 5 days BL-8040 monotherapy followed by repeated 3-week cycles of Pembrolizumab Q3W in combination with BL-8040 TIW for up to two years. Eligibility criteria included second line (2L) or higher metastatic PDAC with measurable disease by RECIST1.1.


As of May 2018, 37 patients were enrolled in the study of which 29 were evaluable (i.e. received at least one dose of combination and have a post baseline CT) and 17 received one previous treatment line (2L). Response by RECIST1.1 for the evaluable population showed 1 subject (3.4%) with partial response and 9 (31%) with stable disease, yielding 34.5% (10 subjects) with disease control. Mismatch repair status is available for 5 patients with disease control, and all are microsatellite stable (MSS). The most common adverse event was injection site reaction (mild to moderate). Median overall survival (OS) in the entire population and in the 2L subgroup is 3.4 and 7.5 months, respectively, with 6-month survival rates of 34.9% and 50.4%, respectively.


PDAC treatment with BL-8040 and Pembrolizumab is safe, tolerable and shows promising OS, particularly in the 2L subgroup of patients that demonstrated median OS of 7.5 months. This is in comparison to the 6.1 months OS of Onivyde + 5-FU/Leucovorin (approved 2L chemotherapy; NAPOLI-1 trial). Furthermore, these results were seen in MSS subjects, resistant to ICIs as single agents.

Clinical trial identification


Legal entity responsible for the study

BioLineRx Ltd.


BioLineRx Ltd, Merck & Co., Inc.

Editorial Acknowledgement


M. Hidalgo: Clinical advisory board member for clinical trial: BioLineRx; External consultant: BioLineRx. R. Epelbaum, B.M. Wolpin, S.M. Stemmer, R. Geva, E. Borazanci, M. Borad, K.S. Pedersen, J.O. Park, R. Ramirez: Participation in the clinical trial sponsored: BioLineRx. T. Golan: Participation in the clinical trial sponsored: BioLineRx; Participation in clinical advisory board: BioLineRx. A. Peled: Participation in pre-clinical and clinical testing and analysis: BioLineRx. T.M. Lustig, O. Bohana Kashtan, O. Rosenfeld: Employee: BioLineRx; E. Sorani, A. Vainstein Haras: Employee: BioLineRx; Senior management member: BiolineRx. K. Schlienger: Employee: Merck. D.D. Von Hoff: External consultant: BioLineRx.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.